Skip to content

Study · Non-randomized trial · n = 15 · 2000

3 results

[B domain mutations in the polymerase gene of hepatitis B virus during combination therapy with thymosin alpha1 and famciclovir in Chinese asymptomatic HBV carriers].

Hou J, Wang Z, Sun J

Zhonghua yi xue za zhi1 Aug 2000

PMID11798819 (opens in a new tab)PepBankPUB-11798819
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialSafety outcome

    In Chinese HBeAg-positive HBV carriers treated with thymosin alpha1 alone, no patient developed amino-acid-changing mutations in the B domain of the HBV polymerase gene.

    In plain wordsIn people with chronic hepatitis B treated with thymosin alpha1 alone, none developed these virus mutations.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeB domain polymerase mutations with thymosin alpha1 alone
    Study

    n = 15

    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    none of the Talpha1 treated patients developed mutations in the 'B domain' of polymerase gene which could result in amino acid changes.
    1 context sentence
    Summary · context
    Sequential sera from 29 Chinese chronic HBeAg positive HBV carriers treated with combination therapy with thymosin alpha1 (Talpha1) plus famciclovir and also from 15 cases treated with Talpha1 alone, were studied.

Studies that did not test the peptide alone2

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 02HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialSafety outcome

    In Chinese HBeAg-positive HBV carriers, nine patients treated with thymosin alpha1 plus famciclovir developed amino-acid-changing mutations in the B domain of the HBV polymerase gene.

    In plain wordsIn people with chronic hepatitis B, nine patients on thymosin alpha1 plus famciclovir developed virus mutations in the polymerase gene.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseB domain polymerase mutations with thymosin alpha1 plus famciclovir
    Study

    n = 29

    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    Nine Talpha1 plus FCV-treated
    1 context sentence
    Summary · context
    Sequential sera from 29 Chinese chronic HBeAg positive HBV carriers treated with combination therapy with thymosin alpha1 (Talpha1) plus famciclovir and also from 15 cases treated with Talpha1 alone, were studied.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 03HumanNot a test of Thymosin alpha-1 aloneNon-randomized trialOther

    In HBV carriers given thymosin alpha1 plus famciclovir, B domain mutations during treatment were significantly associated with HBV DNA rebound.

    In plain wordsIn people with hepatitis B on thymosin alpha1 plus famciclovir, virus mutations were linked to a return of virus DNA.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableAssociation of B domain mutations with HBV DNA rebound
    Study

    n = 29

    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    The development of 'B domain' mutations, during treatment, was significantly associated with HBV DNA rebound in those who received Talpha1 plus FCV.
    1 context sentence
    Summary · context
    Sequential sera from 29 Chinese chronic HBeAg positive HBV carriers treated with combination therapy with thymosin alpha1 (Talpha1) plus famciclovir and also from 15 cases treated with Talpha1 alone, were studied.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.